Product Overview
Blocking/Immunizing peptide for anti-GLIPR1/RTVP-1 antibody
Tag/Conjugate
Unconjugated
Application Notes
For in vitro research use only. Not intended for any diagnostic or therapeutic purpose. Not for human or animal consumption.
Format
Lyophilized powder
Storage
Shipped at ambient temperature, store at -20°C.
Antigen Description
This gene encodes a protein with similarity to both the pathogenesis-related protein (PR) superfamily and the cysteine-rich secretory protein (CRISP) family. Increased expression of this gene is associated with myelomocytic differentiation in macrophage and decreased expression of this gene through gene methylation is associated with prostate cancer. The protein has proapoptotic activities in prostate and bladder cancer cells. This gene is a member of a cluster on chromosome 12 containing two other similar genes. Alternatively spliced variants which encode different protein isoforms have been described; however, not all variants have been fully characterized.
Synonyms
GLIPR1; GLI pathogenesis-related 1; GLI pathogenesis related 1 (glioma); glioma pathogenesis-related protein 1; GliPR; RTVP1; gliPR 1; protein RTVP-1; GLI pathogenesis-related 1 (glioma); testes-specific vespid and pathogenesis protein 1; related to testis-specific, vespid, and pathogenesis proteins 1; GLIPR; CRISP7;
Citations
Have you cited CDBP1372 in a publication?
Let us know and earn a reward for your research.
| Product Name |
Cat. No. |
Applications |
Host Species |
Datasheet |
Price |
Add to Basket |
| Product Name |
Cat. No. |
Applications |
Host Species |
Datasheet |
Price |
Add to Basket |
Chilukamarri, L; Hancock, AL; et al. Hypomethylation and aberrant expression of the glioma pathogenesis-related 1 gene in Wilms tumors. NEOPLASIA 9:970-978(2007).
Quinn, MCJ; Filali-Mouhim, A; et al. Reprogramming of the Transcriptome in a Novel Chromosome 3 Transfer Tumor Suppressor Ovarian Cancer Cell Line Model Affected Molecular Networks That Are Characteristic of Ovarian Cancer. MOLECULAR CARCINOGENESIS 48:648-661(2009).